Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 9/2006

Content (13 Articles)

Original Article

Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide

Supriya Perambakam, Sigrun Hallmeyer, Samarth Reddy, Nadim Mahmud, Linda Bressler, Phillip DeChristopher, Delores Mahmud, Rafael Nunez, Jeffrey A. Sosman, David J. Peace

Original Article

Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease

S.J. Oosterling, G.J. van der Bij, M. Bögels, J.R.M. van der Sijp, R.H.J. Beelen, S. Meijer, M. van Egmond

Original Article

Inhibition of nuclear factor kappa B (NFκB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation

Anahid Jewett, Nicholas A. Cacalano, Antonia Teruel, Marcela Romero, Marjan Rashedi, Meiying Wang, Hiromi Nakamura

Original Article

CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers

Koji Kono, Hiromichi Kawaida, Akihiro Takahashi, Hidemitsu Sugai, Kosaku Mimura, Naoto Miyagawa, Hideo Omata, Hideki Fujii

Original Article

Characterization of the γδ T cell response to acute leukemia

Paul F. Meeh, Michelle King, Rebecca L. O’Brien, Stephanie Muga, Philip Buckhalts, Ronnie Neuberg, Lawrence S. Lamb Jr

Original Article

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

Richard Harrop, Matthew G. Ryan, Kevin A. Myers, Irina Redchenko, Susan M. Kingsman, Miles W. Carroll

Original Article

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment

Maria M. Belimezi, Danai Papanastassiou, Efrossini Merkouri, Constantin N. Baxevanis, Avgi Mamalaki

Original Article

Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy

Evgeny Arons, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Seth M. Steinberg, David J. Liewehr, Ira Pastan, Robert J. Kreitman

Original Article

The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor

Ye Qing, Wang Shuo, Wang Zhihua, Zhu Huifen, Lei Ping, Liu Lijiang, Zhao Xiaorong, Chao Liming, Xiao Daiwen, Huang Yu, Xing Wei, Fang Min, Feng Zuohua, Shen Guanxin

Original Article

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity

Takuya Osada, Timothy Clay, Amy Hobeika, H. Kim Lyerly, Michael A. Morse

Original Article

A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes

Niels Schaft, Jan Dörrie, Ina Müller, Verena Beck, Stefanie Baumann, Tanja Schunder, Eckhart Kämpgen, Gerold Schuler

Original Article

T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells

Gretchen E. Lyons, Jeffrey J. Roszkowski, Stephen Man, Cassian Yee, W. Martin Kast, Michael I. Nishimura

Original Article

Effect of interleukin-18 on metastasis of mouse osteosarcoma cells

Yoshiteru Nakamura, Naoko Yamada, Hideki Ohyama, Keiji Nakasho, Yasuko Nishizawa, Takuya Okamoto, Hiroyuki Futani, Shinichi Yoshiya, Haruki Okamura, Nobuyuki Terada

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine